30 TECHNOLOGY DRIVE, WARREN, NJ
Investor Presentation
Announces $75M Strategic Funding Agreement to Support the Potential Launch of Anaphylm™
Reports Second Quarter 2025 Financial Results and Provides Business Update
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 424(b)(2)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence